297 related articles for article (PubMed ID: 30759374)
1. Phosphodiesterases as therapeutic targets for respiratory diseases.
Zuo H; Cattani-Cavalieri I; Musheshe N; Nikolaev VO; Schmidt M
Pharmacol Ther; 2019 May; 197():225-242. PubMed ID: 30759374
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
3. Selective PDE inhibitors as novel treatments for respiratory diseases.
Page CP; Spina D
Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Spina D
Drugs; 2003; 63(23):2575-94. PubMed ID: 14636078
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences.
Contreras S; Milara J; Morcillo E; Cortijo J
Curr Pharm Des; 2017; 23(14):2073-2083. PubMed ID: 28201975
[TBL] [Abstract][Full Text] [Related]
6. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotides and phosphodiesterases and airway function.
Barnes PJ
Eur Respir J; 1995 Mar; 8(3):457-62. PubMed ID: 7789494
[TBL] [Abstract][Full Text] [Related]
9. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
Kokkonen K; Kass DA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
[TBL] [Abstract][Full Text] [Related]
10. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
Keravis T; Lugnier C
Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
Brescia M; Zaccolo M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
[TBL] [Abstract][Full Text] [Related]
12. Experimental and investigational phosphodiesterase inhibitors in development for asthma.
Ntontsi P; Detta A; Bakakos P; Loukides S; Hillas G
Expert Opin Investig Drugs; 2019 Mar; 28(3):261-266. PubMed ID: 30678501
[TBL] [Abstract][Full Text] [Related]
13. Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?
Lugnier C; Meyer A; Talha S; Geny B
Pharmacol Ther; 2020 Apr; 208():107475. PubMed ID: 31926200
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
Preedy MEJ
Cardiovasc Drugs Ther; 2020 Jun; 34(3):401-417. PubMed ID: 32172427
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase-4 inhibitor therapy for lung diseases.
Beghè B; Rabe KF; Fabbri LM
Am J Respir Crit Care Med; 2013 Aug; 188(3):271-8. PubMed ID: 23656508
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase in heart and vessels: from physiology to diseases.
Fu Q; Wang Y; Yan C; Xiang YK
Physiol Rev; 2024 Apr; 104(2):765-834. PubMed ID: 37971403
[TBL] [Abstract][Full Text] [Related]
17. Cigarette smoke exposure alters phosphodiesterases in human structural lung cells.
Zuo H; Faiz A; van den Berge M; Mudiyanselage SNHR; Borghuis T; Timens W; Nikolaev VO; Burgess JK; Schmidt M
Am J Physiol Lung Cell Mol Physiol; 2020 Jan; 318(1):L59-L64. PubMed ID: 31664853
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
Barnette MS
Prog Drug Res; 1999; 53():193-229. PubMed ID: 10616299
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterases in the vascular system.
Matsumoto T; Kobayashi T; Kamata K
J Smooth Muscle Res; 2003 Aug; 39(4):67-86. PubMed ID: 14692693
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of phosphodiesterase as cancer therapeutics.
Peng T; Gong J; Jin Y; Zhou Y; Tong R; Wei X; Bai L; Shi J
Eur J Med Chem; 2018 Apr; 150():742-756. PubMed ID: 29574203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
